The field of cancer therapy has evolved immensely over the last 10 years. However, a comprehensive and up-to-date analysis of the global lung cancer therapeutic landscape has been lacking for all these years.
Here, I provide a systematic analysis of more than 700 drugs or therapeutic entities developed in approximately 30 countries or regions. This analysis informs about the clinical stage and specific biological targets for the lung cancer drugs.
This study benefits a multitude of entities by:
- educating the medical oncologists and drug developers about newly available therapies
- allowing research scientists to formulate new hypotheses and establish collaborations
- providing lung cancer patients with hope about newly available therapies
This project is a collaboration with Drs. Upal Basu Roy and Amy C. Moore at LUNGevity foundation, USA.
The published research paper from this project is here.